Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy



Status:Withdrawn
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2006
End Date:December 2009

Use our guide to learn which trials are right for you!

The purpose of this study is to see what kinds of breast tumors will respond to lapatinib.
Lapatinib is an experimental medicine which may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.


Inclusion Criteria:

- Histologically or cytologically-confirmed by either core or fine needle biopsy
primary invasive carcinoma of the breast;

- AJCC T2-T3 disease (>2.0 cm without chest wall or skin invasion) by at least one
imaging modality (either mammogram, ultrasound, or MRI) - entry criteria is based on
radiologic staging and not final pathologic staging;

- ECOG performance status 0-1 (Karnofsky ≥ 70%

- Any lymph node status, hormone receptor status, and level of erbB2 expression

- No prior chemotherapy, hormonal therapy or radiation therapy to the affected breast
for current or previous malignancy;

- Cardiac ejection fraction >50% or within the institutional range of normal;

- Patients must have normal organ and marrow function defined as: Leukocyte count
>3000/uL; Absolute neutrophil count (ANC) ≥ 1,500/mm3, platelets > 100,000/mm3, and
hemoglobin ≥ 8 gm/dl; Serum creatinine ≤ 1.5 times ULN, or 24-hour creatinine
clearance ≥ 75 cc/min; Serum bilirubin ≤ 1.5 times ULN; SGOT ≤ 2.5 times ULN;
alkaline phosphatase ≤ 2.5 ULN times ULN.

- The effects of lapatinib on the developing human fetus at the recommended therapeutic
dose are unknown. For this reason, women of child-bearing potential and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she must inform her treating physician immediately.

- Ability to understand and the willingness to sign written informed consent document.

Exclusion Criteria:

- AJCC T1, T4, or stage 4 disease;

- Patients may not have undergone incisional or excisional biopsy of their tumor;

- Patients may not be receiving any other investigational agents;

- Absolute contraindication to MRI imaging (cardiac pacemaker or any non-removable
metallic foreign object in the body);

- On chronic therapy with any known inducer or inhibitor of CYP3A4

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant or lactating women are excluded from this study because lapatinib is a
tyrosine kinase inhibitor with the potential for teratogenic or abortifacient
effects.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials